Haier Biomedical's 2026 Interim Report Shows Net Profit of 147 Million Yuan, Up 3.28% Year-on-Year

Jiemian··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Haier Biomedical released its 2026 interim report, with net profit attributable to the parent company at 147 million yuan, up 3.28% from the same period last year. Total operating revenue was 1.296 billion yuan, up 8.45% year-on-year. Net cash inflow from operating activities was 144 million yuan, up 304.81% year-on-year. The company's latest asset-liability ratio was 19.86%, gross margin was 47.13%, and diluted earnings per share was 0.47 yuan.

Impact on assets 1

Others▲